- Home
- TARA vs PNNT Comparison
TARA vs PNNT Comparison
Compare TARA & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARA | PNNT |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.5M | 285.3M |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TARA | PNNT |
|---|---|---|
| Price | $5.17 | $4.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $23.60 | $5.75 |
| AVG Volume (30 Days) | 523.4K | ★ 654.6K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 21.05% |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $4.29 |
| 52 Week High | $7.82 | $7.53 |
Technical Indicators
Market Signals| Indicator | TARA | PNNT |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 45.25 |
| Support Level | $4.92 | $4.40 |
| Resistance Level | $5.44 | $4.75 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 41.54 | 38.75 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.